FDA grants approval of Nextstellis (3 mg drospirenone/14.2 mg estetrol) tablets for contraception

Approval based on two Phase 3 studies (n=3,725) which demonstrated that Nextstellis, first contraceptive containing a plant based estrogen, met primary efficacy endpoint of pregnancy prevention and secondary endpoints of cycle control, bleeding control, safety, and tolerability.

Source:

Biospace Inc.